Skip to main content
×
Home
    • Aa
    • Aa

Molecular mechanisms of antibody-mediated neutralisation of flavivirus infection

  • Theodore C. Pierson (a1) and Michael S. Diamond (a2)
Abstract
Abstract

Flaviviruses are a group of positive-stranded RNA viruses that cause a spectrum of severe illnesses globally in more than 50 million individuals each year. While effective vaccines exist for three members of this group (yellow fever, Japanese encephalitis, and tick-borne encephalitis viruses), safe and effective vaccines for several other flaviviruses of clinical importance, including West Nile and dengue viruses, remain in development. An effective humoral immune response is critical for protection against flaviviruses and an essential goal of vaccine development. The effectiveness of virus-specific antibodies in vivo reflects their capacity to inhibit virus entry and spread through several mechanisms, including the direct neutralisation of virus infection. Recent advances in our understanding of the structural biology of flaviviruses, coupled with the use of small-animal models of flavivirus infection, have promoted significant advances in our appreciation of the factors that govern antibody recognition and inhibition of flaviviruses in vitro and in vivo. In this review, we discuss the properties that define the potency of neutralising antibodies and the molecular mechanisms by which they inhibit virus infection. How recent advances in this area have the potential to improve the development of safe and effective vaccines and immunotherapeutics is also addressed.

Copyright
Corresponding author
*Corresponding author: Theodore C. Pierson, Laboratory of Viral Diseases, NIAID, NIH, 33 North Drive, Room 1E19A.2, Bethesda, MD 20814, USA. Tel: +1 301 451 7977; Fax: 1 301 451 7978; E-mail: piersontc@mail.nih.gov
Linked references
Hide All

This list contains references from the content that can be linked to their source. For a full set of references and notes please see the PDF or HTML where available.

2 Y. Zhang (2004) Conformational changes of the flavivirus E glycoprotein. Structure 12, 1607-1618

3 F.A. Rey (1995) The envelope glycoprotein from tick-borne encephalitis virus at 2 A resolution. Nature 375, 291-298

4 Y. Modis (2003) A ligand-binding pocket in the dengue virus envelope glycoprotein. Proc Natl Acad Sci U S A 100, 6986-6991

5 Y. Modis (2005) Variable surface epitopes in the crystal structure of dengue virus type 3 envelope glycoprotein. J Virol 79, 1223-1231

6 J.J. Chu (2005) Inhibition of West Nile virus entry by using a recombinant domain III from the envelope glycoprotein. J Gen Virol 86, 405-412

7 S.L. Allison (2001) Mutational evidence for an internal fusion peptide in flavivirus envelope protein E. J Virol 75, 4268-4275

8 Y. Modis (2004) Structure of the dengue virus envelope protein after membrane fusion. Nature 427, 313-319

9 S. Bressanelli (2004) Structure of a flavivirus envelope glycoprotein in its low-pH-induced membrane fusion conformation. EMBO J 23, 728-738

10 W. Zhang (2003) Visualization of membrane protein domains by cryo-electron microscopy of dengue virus. Nat Struct Biol 10, 907-912

13 J.M. Mackenzie and E.G. Westaway (2001) Assembly and maturation of the flavivirus Kunjin virus appear to occur in the rough endoplasmic reticulum and along the secretory pathway, respectively. J Virol 75, 10787-10799

14 Y. Zhang (2007) Structure of immature West Nile virus. J Virol 81, 6141-6145

15 Y. Zhang (2003) Structures of immature flavivirus particles. EMBO J 22, 2604-2613

16 F.X. Heinz (1994) Structural changes and functional control of the tick-borne encephalitis virus glycoprotein E by the heterodimeric association with protein prM. Virology 198, 109-117

17 F. Guirakhoo (1991) Fusion activity of flaviviruses: comparison of mature and immature (prM-containing) tick-borne encephalitis virions. J Gen Virol 72, 1323-1329

18 S. Mukhopadhyay , R.J. Kuhn and M.G. Rossmann (2005) A structural perspective of the flavivirus life cycle. Nat Rev Microbiol 3, 13-22

20 S. Mukhopadhyay (2003) Structure of West Nile virus. Science 302, 248

21 R.J. Kuhn (2002) Structure of dengue virus: implications for flavivirus organization, maturation, and fusion. Cell 108, 717-725

22 T. Kimura , S.W. Gollins and J.S. Porterfield (1986) The effect of pH on the early interaction of West Nile virus with P388D1 cells. J Gen Virol 67, 2423-2433

23 S.W. Gollins and J.S. Porterfield (1986) pH-dependent fusion between the flavivirus West Nile and liposomal model membranes. J Gen Virol 67, 157-166

24 H. Holzmann (1995) Tick-borne encephalitis virus envelope protein E-specific monoclonal antibodies for the study of low pH-induced conformational changes and immature virions. Arch Virol 140, 213-221

26 K. Stiasny (2001) Role of metastability and acidic pH in membrane fusion by tick-borne encephalitis virus. J Virol 75, 7392-7398

28 D.M. Eckert and P.S. Kim (2001) Mechanisms of viral membrane fusion and its inhibition. Annu Rev Biochem 70, 777-810

29 P.M. Colman and M.C. Lawrence (2003) The structural biology of type I viral membrane fusion. Nat Rev Mol Cell Biol 4, 309-319

30 M. Liao and M. Kielian (2005) Domain III from class II fusion proteins functions as a dominant-negative inhibitor of virus membrane fusion. J Cell Biol 171, 111-120

31 F. Bai (2007) Antiviral peptides targeting the west nile virus envelope protein. J Virol 81, 2047-2055

32 Y.M. Hrobowski , R.F. Garry and S.F. Michael (2005) Peptide inhibitors of dengue virus and West Nile virus infectivity. Virol J 2, 49

33 J.D. Reeves and A.J. Piefer (2005) Emerging drug targets for antiretroviral therapy. Drugs 65, 1747-1766

34 M.S. Diamond (2003) B cells and antibody play critical roles in the immediate defense of disseminated infection by West Nile encephalitis virus. J Virol 77, 2578-2586

35 M.S. Diamond (2003) Innate and adaptive immune responses determine protection against disseminated infection by West Nile encephalitis virus. Viral Immunol 16, 259-278

36 T. Oliphant (2005) Development of a humanized monoclonal antibody with therapeutic potential against West Nile virus. Nat Med 11, 522-530

37 R.B. Tesh (2002) Immunization with heterologous flaviviruses protective against fatal West Nile encephalitis. Emerg Infect Dis 8, 245-251

38 T. Wang (2001) Immunization of mice against West Nile virus with recombinant envelope protein. J Immunol 167, 5273-5277

39 D. Ben-Nathan (2003) Prophylactic and therapeutic efficacy of human intravenous immunoglobulin in treating west nile virus infection in mice. J Infect Dis 188, 5-12

40 D.L. Camenga , N. Nathanson and G.A. Cole (1974) Cyclophosphamide-potentiated West Nile viral encephalitis: relative influence of cellular and humoral factors. J Infect Dis 130, 634-641

41 J.T. Roehrig (2001) Antibody prophylaxis and therapy for flavivirus encephalitis infections. Ann N Y Acad Sci 951, 286-297

43 T.R. Kreil (1997) Antibodies protect mice against challenge with tick-borne encephalitis virus (TBEV)-infected macrophages. Clin Exp Immunol 110, 358-361

45 D.W. Beasley (2004) Protection against Japanese encephalitis virus strains representing four genotypes by passive transfer of sera raised against ChimeriVax-JE experimental vaccine. Vaccine 22, 3722-3726

46 S. Vazquez (2002) Immune response to synthetic peptides of dengue prM protein. Vaccine 20, 1823-1830

47 S. Pincus (1992) Recombinant vaccinia virus producing the prM and E proteins of yellow fever virus protects mice from lethal yellow fever encephalitis. Virology 187, 290-297

49 G. Colombage (1998) DNA-based and alphavirus-vectored immunisation with prM and E proteins elicits long-lived and protective immunity against the flavivirus, Murray Valley encephalitis virus. Virology 250, 151-163

50 K.M. Chung (2007) Antibody recognition of cell surface-associated NS1 triggers Fc-gamma receptor-mediated phagocytosis and clearance of West Nile Virus-infected cells. J Virol 81, 9551-9555

51 K.M. Chung (2006) Antibodies against West Nile Virus nonstructural protein NS1 prevent lethal infection through Fc gamma receptor-dependent and -independent mechanisms. J Virol 80, 1340-1351

52 P.Y. Shu (2000) Dengue NS1-specific antibody responses: isotype distribution and serotyping in patients with Dengue fever and Dengue hemorrhagic fever. J Med Virol 62, 224-232

54 C.A. Gibson , J.J. Schlesinger and A.D. Barrett (1988) Prospects for a virus non-structural protein as a subunit vaccine. Vaccine 6, 7-9

55 D.W. Beasley and A.D. Barrett (2002) Identification of neutralizing epitopes within structural domain III of the West Nile virus envelope protein. J Virol 76, 13097-13100

56 T. Oliphant (2006) Antibody recognition and neutralization determinants on domains I and II of West Nile Virus envelope protein. J Virol 80, 12149-12159

57 W.D. Crill and G.J. Chang (2004) Localization and characterization of flavivirus envelope glycoprotein cross-reactive epitopes. J Virol 78, 13975-13986

58 J.T. Roehrig , R.A. Bolin and R.G. Kelly (1998) Monoclonal antibody mapping of the envelope glycoprotein of the dengue 2 virus, Jamaica. Virology 246, 317-328

59 J.T. Roehrig , J.H. Mathews and D.W. Trent (1983) Identification of epitopes on the E glycoprotein of Saint Louis encephalitis virus using monoclonal antibodies. Virology 128, 118-126

60 F.X. Heinz (1983) A topological and functional model of epitopes on the structural glycoprotein of tick-borne encephalitis virus defined by monoclonal antibodies. Virology 126, 525-537

62 S. Sukupolvi-Petty (2007) Type- and subcomplex-specific neutralizing antibodies against domain III of dengue virus type 2 envelope protein recognize adjacent epitopes. J Virol 81, 12816-12826

63 M. Throsby (2006) Isolation and characterization of human monoclonal antibodies from individuals infected with West Nile Virus. J Virol 80, 6982-6992

64 T. Oliphant (2007) Induction of epitope-specific neutralizing antibodies against West Nile virus. J Virol 81, 11828-11839

65 M.D. Sanchez (2007) The neutralizing antibody response against West Nile virus in naturally infected horses. Virology 359, 336-348

68 T.C. Pierson (2007) Stoichiometric requirements for antibody-mediated neutralization and enhancement of West Nile virus infection. Cell Host Microbe 1, 135-146

70 G.D. Gromowski and A.D. Barrett (2007) Characterization of an antigenic site that contains a dominant, type-specific neutralization determinant on the envelope protein domain III (ED3) of dengue 2 virus. Virology 366, 349-360

71 K. Stiasny (2006) Cryptic properties of a cluster of dominant flavivirus cross-reactive antigenic sites. J Virol 80, 9557-9568

72 J.D. Morrey (2006) Humanized monoclonal antibody against West Nile virus envelope protein administered after neuronal infection protects against lethal encephalitis in hamsters. J Infect Dis 194, 1300-1308

73 J.D. Morrey (2007) Defining limits of treatment with humanized neutralizing monoclonal antibody for West Nile virus neurological infection in a hamster model. Antimicrob Agents Chemother 51, 2396-2402

74 G.E. Nybakken (2005) Structural basis of West Nile virus neutralization by a therapeutic antibody. Nature 437, 764-769

75 B. Kaufmann (2006) West Nile virus in complex with the Fab fragment of a neutralizing monoclonal antibody. Proc Natl Acad Sci U S A 103, 12400-12404

76 M.N. Krishnan (2007) Rab 5 is required for the cellular entry of dengue and West Nile viruses. J Virol 81, 4881-4885

77 H.M. van der Schaar (2007) Characterization of the early events in dengue virus cell entry by biochemical assays and single-virus tracking. J Virol 81, 12019-12028

78 S.W. Gollins and J.S. Porterfield (1985) Flavivirus infection enhancement in macrophages: an electron microscopic study of viral cellular entry. J Gen Virol 66, 1969-1982

79 J.J. Chu and M.L. Ng (2004) Infectious entry of West Nile virus occurs through a clathrin-mediated endocytic pathway. J Virol 78, 10543-10555

80 R. Anderson (2003) Manipulation of cell surface macromolecules by flaviviruses. Adv Virus Res 59, 229-274

81 K. Stiasny , C. Koessl and F.X. Heinz (2003) Involvement of lipids in different steps of the flavivirus fusion mechanism. J Virol 77, 7856-7862

82 K. Stiasny (2002) Membrane interactions of the tick-borne encephalitis virus fusion protein E at low pH. J Virol 76, 3784-3790

83 R. Pantophlet and D.R. Burton (2006) GP120: target for neutralizing HIV-1 antibodies. Annu Rev Immunol 24, 739-769

84 R.T. He (1995) Antibodies that block virus attachment to Vero cells are a major component of the human neutralizing antibody response against dengue virus type 2. J Med Virol 45, 451-461

85 A.D. Jennings (1994) Analysis of a yellow fever virus isolated from a fatal case of vaccine-associated human encephalitis. J Infect Dis 169, 512-518

86 C.W. Mandl (2000) Attenuation of tick-borne encephalitis virus by structure-based site-specific mutagenesis of a putative flavivirus receptor binding site. J Virol 74, 9601-9609

88 W.R. Jiang (1993) Single amino acid codon changes detected in louping ill virus antibody-resistant mutants with reduced neurovirulence. J Gen Virol 74, 931-935

89 B. Tassaneetrithep (2003) DC-SIGN (CD209) mediates dengue virus infection of human dendritic cells. J Exp Med 197, 823-829

90 E. Navarro-Sanchez (2003) Dendritic-cell-specific ICAM3-grabbing non-integrin is essential for the productive infection of human dendritic cells by mosquito-cell-derived dengue viruses. EMBO Rep 4, 723-728

91 A. Sakuntabhai (2005) A variant in the CD209 promoter is associated with severity of dengue disease. Nat Genet 37, 507-513

92 P.Y. Lozach (2005) Dendritic cell-specific intercellular adhesion molecule 3-grabbing non-integrin (DC-SIGN)-mediated enhancement of dengue virus infection is independent of DC-SIGN internalization signals. J Biol Chem 280, 23698-23708

93 C.W. Davis (2006) The location of asparagine-linked glycans on West Nile virions controls their interactions with CD209 (dendritic cell-specific ICAM-3 grabbing nonintegrin). J Biol Chem 281, 37183-37194

94 C.W. Davis (2006) West Nile virus discriminates between DC-SIGN and DC-SIGNR for cellular attachment and infection. J Virol 80, 1290-1301

95 E. Pokidysheva (2006) Cryo-EM reconstruction of dengue virus in complex with the carbohydrate recognition domain of DC-SIGN. Cell 124, 485-493

96 D.A. Mitchell , A.J. Fadden and K. Drickamer (2001) A novel mechanism of carbohydrate recognition by the C-type lectins DC-SIGN and DC-SIGNR. Subunit organization and binding to multivalent ligands. J Biol Chem 276, 28939-28945

97 S.W. Gollins and J.S. Porterfield (1986) A new mechanism for the neutralization of enveloped viruses by antiviral antibody. Nature 321, 244-246

98 G.E. Nybakken (2006) Crystal structure of the west nile virus envelope glycoprotein. J Virol 80, 11467-11474

99 K. Stiasny (2007) Probing the flavivirus membrane fusion mechanism by using monoclonal antibodies. J Virol 81, 11526-11531

100 E. Mehlhop (2005) Complement activation is required for induction of a protective antibody response against West Nile virus infection. J Virol 79, 7466-7477

101 E. Mehlhop and M.S. Diamond (2006) Protective immune responses against West Nile virus are primed by distinct complement activation pathways. J Exp Med 203, 1371-1381

102 K. Meyer (2002) Complement-mediated enhancement of antibody function for neutralization of pseudotype virus containing hepatitis C virus E2 chimeric glycoprotein. J Virol 76, 2150-2158

103 J.Q. Feng , K. Mozdzanowska and W. Gerhard (2002) Complement component C1q enhances the biological activity of influenza virus hemagglutinin-specific antibodies depending on their fine antigen specificity and heavy-chain isotype. J Virol 76, 1369-1378

104 J.J. Schlesinger and S. Chapman (1995) Neutralizing F(ab')2 fragments of protective monoclonal antibodies to yellow fever virus (YF) envelope protein fail to protect mice against lethal YF encephalitis. J Gen Virol 76, 217-220

105 J.J. Schlesinger , M. Foltzer and S. Chapman (1993) The Fc portion of antibody to yellow fever virus NS1 is a determinant of protection against YF encephalitis in mice. Virology 192, 132-141

106 S.B. Halstead (2003) Neutralization and antibody-dependent enhancement of dengue viruses. Adv Virus Res 60, 421-467

107 A.L. Rothman (2003) Immunology and immunopathogenesis of dengue disease. Adv Virus Res 60, 397-419

108 D.W. Vaughn (2000) Dengue viremia titer, antibody response pattern, and virus serotype correlate with disease severity. J Infect Dis 181, 2-9

111 W.B. Klimstra (2005) Targeting Sindbis virus-based vectors to Fc receptor-positive cell types. Virology 338, 9-21

112 I.D. Iankov (2006) Immunoglobulin g antibody-mediated enhancement of measles virus infection can bypass the protective antiviral immune response. J Virol 80, 8530-8540

113 K.J. Huang (2006) The dual-specific binding of dengue virus and target cells for the antibody-dependent enhancement of dengue virus infection. J Immunol 176, 2825-2832

114 M.J. Wallace (2003) Antibody-dependent enhancement of Murray Valley encephalitis virus virulence in mice. J Gen Virol 84, 1723-1728

115 A. Takada (2003) Antibody-dependent enhancement of Ebola virus infection. J Virol 77, 7539-7544

116 J. Girn , M. Kavoosi and J. Chantler (2002) Enhancement of coxsackievirus B3 infection by antibody to a different coxsackievirus strain. J Gen Virol 83, 351-358

118 A. Takeda , C.U. Tuazon and F.A. Ennis (1988) Antibody-enhanced infection by HIV-1 via Fc receptor-mediated entry. Science 242, 580-583

119 M. Tamura , R.G. Webster and F.A. Ennis (1991) Antibodies to HA and NA augment uptake of influenza A viruses into cells via Fc receptor entry. Virology 182, 211-219

120 D.M. Morens and S.B. Halstead (1990) Measurement of antibody-dependent infection enhancement of four dengue virus serotypes by monoclonal and polyclonal antibodies. J Gen Virol 71, 2909-2914

121 D.M. Morens , S.B. Halstead and N.J. Marchette (1987) Profiles of antibody-dependent enhancement of dengue virus type 2 infection. Microb Pathog 3, 231-237

123 H.B. Gimenez , H.M. Keir and P. Cash (1989) In vitro enhancement of respiratory syncytial virus infection of U937 cells by human sera. J Gen Virol 70, 89-96

126 E.A. Gould and A. Buckley (1989) Antibody-dependent enhancement of yellow fever and Japanese encephalitis virus neurovirulence. J Gen Virol 70, 1605-1608

127 A.D. Barrett and E.A. Gould (1986) Antibody-mediated early death in vivo after infection with yellow fever virus. J Gen Virol 67, 2539-2542

128 J.J. Schlesinger and M.W. Brandriss (1981) Antibody-mediated infection of macrophages and macrophage-like cell lines with 17D-yellow fever virus. J Med Virol 8, 103-117

130 S.B. Halstead and E.J. O'Rourke (1977) Dengue viruses and mononuclear phagocytes. I. Infection enhancement by non-neutralizing antibody. J Exp Med 146, 201-217

131 A.P. Goncalvez (2007) Monoclonal antibody-mediated enhancement of dengue virus infection in vitro and in vivo and strategies for prevention. Proc Natl Acad Sci U S A 104, 9422-9427

132 S.B. Halstead (1979) In vivo enhancement of dengue virus infection in rhesus monkeys by passively transferred antibody. J Infect Dis 140, 527-533

133 E. Mehlhop (2007) Complement protein C1q inhibits antibody-dependent enhancement of flavivirus infection in an IgG subclass-specific manner. Cell Host Microbe 2, 417-426

135 S.W. Gollins and J.S. Porterfield (1984) Flavivirus infection enhancement in macrophages: radioactive and biological studies on the effect of antibody on viral fate. J Gen Virol 65, 1261-1272

137 A. Suhrbier and M. La Linn (2003) Suppression of antiviral responses by antibody-dependent enhancement of macrophage infection. Trends Immunol 24, 165-168

138 D. Hober (2001) Antibody-dependent enhancement of coxsackievirus B4 infectivity of human peripheral blood mononuclear cells results in increased interferon-alpha synthesis. J Infect Dis 184, 1098-1108

139 B.A. Lidbury and S. Mahalingam (2000) Specific ablation of antiviral gene expression in macrophages by antibody-dependent enhancement of Ross River virus infection. J Virol 74, 8376-8381

140 S. Mahalingam and B.A. Lidbury (2003) Antibody-dependent enhancement of infection: bacteria do it too. Trends Immunol 24, 465-467

141 A. Hamdan (2002) Possible benefit of intravenous immunoglobulin therapy in a lung transplant recipient with West Nile virus encephalitis. Transpl Infect Dis 4, 160-162

142 Z. Shimoni (2001) Treatment of West Nile virus encephalitis with intravenous immunoglobulin. Emerg Infect Dis 7, 759

S.S. Whitehead (2007) Prospects for a dengue virus vaccine. Nat Rev Microbiol 5, 518-528

K. Stiasny and F.X. Heinz (2006) Flavivirus membrane fusion. J Gen Virol 87, 2755-2766

J.S. Mackenzie , D.J. Gubler and L.R. Petersen (2004) Emerging flaviviruses: the spread and resurgence of Japanese encephalitis, West Nile and dengue viruses. Nat Med 10, S98-109

A.J. Della-Porta and E.G. Westaway (1978) A multi-hit model for the neutralization of animal viruses. J Gen Virol 38, 1-19

P.J. Klasse and Q.J. Sattentau (2002) Occupancy and mechanism in antibody-mediated neutralization of animal viruses. J Gen Virol 83, 2091-2108

T.J. Smith (2003) Structural studies on antibody-virus complexes. Adv Protein Chem 64, 409-453

L. Hangartner , R.M. Zinkernagel and H. Hengartner (2006) Antiviral antibody responses: the two extremes of a wide spectrum. Nat Rev Immunol 6, 231-243

Recommend this journal

Email your librarian or administrator to recommend adding this journal to your organisation's collection.

Expert Reviews in Molecular Medicine
  • ISSN: -
  • EISSN: 1462-3994
  • URL: /core/journals/expert-reviews-in-molecular-medicine
Please enter your name
Please enter a valid email address
Who would you like to send this to? *
×

Metrics

Altmetric attention score

Full text views

Total number of HTML views: 9
Total number of PDF views: 31 *
Loading metrics...

Abstract views

Total abstract views: 245 *
Loading metrics...

* Views captured on Cambridge Core between September 2016 - 27th May 2017. This data will be updated every 24 hours.